Results 161 to 170 of about 30,153 (204)
Some of the next articles are maybe not open access.
The Journal of Steroid Biochemistry and Molecular Biology, 2007
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon +9 more
openaire +2 more sources
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon +9 more
openaire +2 more sources
Aromatase inhibitors for chemoprevention
Best Practice & Research Clinical Endocrinology & Metabolism, 2004Pre-clinical, molecular and epidemiological evidence supports a role for estrogen in both the initiation and promotion of breast cancer. Antagonizing estrogen has therefore been proposed as one way of reducing risk. Tamoxifen, which competes with estrogen at the estrogen receptor, has been shown in four phase III clinical trials to reduce tumour ...
Paul E, Goss, Kathrin, Strasser-Weippl
openaire +2 more sources
Aromatase, Aromatase Inhibitors, and Breast Cancer
American Journal of Therapeutics, 2001Estrogens are involved in numerous physiologic processes and have crucial roles in particular disease states, such as mammary carcinomas. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P-450 enzyme complex called aromatase.
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 1990
Aminoglutethimide (AG), an inhibitor of the aromatase enzyme, inhibits the biosynthesis of estrogens and displays well-documented anti-tumor efficacy in breast-cancer. However, this efficacy is accompanied by a relative lack of specificity in inhibiting aromatase and moderate tolerability.
A S, Bhatnagar +5 more
openaire +2 more sources
Aminoglutethimide (AG), an inhibitor of the aromatase enzyme, inhibits the biosynthesis of estrogens and displays well-documented anti-tumor efficacy in breast-cancer. However, this efficacy is accompanied by a relative lack of specificity in inhibiting aromatase and moderate tolerability.
A S, Bhatnagar +5 more
openaire +2 more sources
Inhibition of Aromatase in Vitro and in Vivo by Aromatase Inhibitors
Journal of Enzyme Inhibition, 1990(1990). Inhibition of Aromatase in Vitro and in Vivo by Aromatase Inhibitors. Journal of Enzyme Inhibition: Vol. 4, No. 2, pp. 179-186.
A S, Bhatnagar +2 more
openaire +2 more sources
Aromatase inhibitors and teratogenesis
Fertility and Sterility, 2004letter to the ...
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 2007
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
Aromatase inhibitors and the endometrium
Maturitas, 2008To investigate the potential impact of aromatase inhibitors, given after stopping tamoxifen treatment, on the endometrium of postmenopausal breast cancer patients.Review of all available literature of studies on aromatase inhibitor therapy in postmenopausal breast cancer patients previously treated with tamoxifen.(1) Endometrial thickness was found to ...
openaire +2 more sources
Aromatase inhibitors—Socioeconomical issues
The Journal of Steroid Biochemistry and Molecular Biology, 2005Novel, third-generation aromatase inhibitors are currently implemented for treatment of postmenopausal breast cancer in the metastatic and adjuvant setting and, potentially, for breast cancer prevention. Introduction of novel therapeutic strategies to large patient groups may add significant costs to health care budgets, forcing institutions to focus ...
Per E, Lønning, Jürgen, Geisler
openaire +3 more sources
Aromatase inhibitors and breast cancer
hmbci, 2012Abstract Breast cancer is the most prevalent cancer and the second leading cause of death among women worldwide. The advent of hormonal therapy has revolutionized the treatment for breast cancer for a century. In the 1960s, an important advance was the development of the antiestrogen tamoxifen.
Saranya, Chumsri, Angela, Brodie
openaire +2 more sources